Johanna Schleutker
PhD, Professor of Medical Genetics
Cancer, Infections and Immunity johanna.schleutker@utu.fi +358 29 450 2726 +358 50 443 7237 Kiinamyllynkatu 10 Turku ORCID identifier: https://orcid.org/0000-0002-1863-0305 |
Cancer genetics; hereditary cancer; genomics; human genetics
Johanna Schleutker got her PhD in 1995 in University of Turku, Faculty of Medicine.The topic of her doctoral thesis was "Linkage disequilibrium is Salla disease; positioning of the sialic acid transport defect". She then moved to University of Tampere, and did her post doc in 1996-1998 in the Cancer Genetics research group of Professor Olli Kallioniemi. Her career continued in the US where she spent the years of 1999-2000 working as a research associate at the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. During the NIH years, she studied genetics of familial prostate cancer in the group of Dr. Jeffrey M.Trent. After her return to Finland, Schleutker started her own research group in 2001 at the Insitute of Medical Technology, University of Tampere, and has ever since focused her studies on genetics and genetic susceptibility of prostate and breast cancer. Schleutker got a professorship in University of Tampere in 2008. In 2011 she started as a professor of medical genetics in University of Turku.
The Schleutker group "Genetic Predisposition to Cancer" is studying both breast and prostate cancer genetics, the main emphasis being on prostate cancer. Of all cancers, prostate cancer (PrCa) has been reported as one of the most heritable diseases: genetic factors have been estimated to account for 57% of the risk. The goal is to identify and characterize predisposing genes and variants, especially those affecting aggressive outcome, including treatment responses to therapies. Further, the aim is to develop tools for prognostic purposes, i.e. prognostic biomarkers. The group has identified many significant genomic risk regions, candidate genes and variants, which have been then further profiled and characterized by functional studies. The group has produced (by 2021) 12 PhD degrees and published over 190 original, peer-reviewed articles in international journals.
Genetics, cancer genetics, hereditary cancer, genomics, molecular biology.
- A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer (2015)
- Cancer Discovery
(A1 Refereed original research article in a scientific journal) - Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer (2015)
- International Journal of Cancer
(A1 Refereed original research article in a scientific journal) - Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer (2015)
- Clinical Genetics
(A1 Refereed original research article in a scientific journal) - Genome-Wide Association Study of Prostate Cancer–Specific Survival (2015)
- Cancer Epidemiology, Biomarkers and Prevention
(A1 Refereed original research article in a scientific journal) - MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families (2015)
- PLoS ONE
(A1 Refereed original research article in a scientific journal) - Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans (2015)
- Human Molecular Genetics
(A1 Refereed original research article in a scientific journal) - Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin (2015)
- European Urology
(A1 Refereed original research article in a scientific journal) - Prediction of Individual Genetic Risk to Prostate Cancer Using a Polygenic Score (2015)
- Prostate
(A1 Refereed original research article in a scientific journal) - Prostate Cancer Screening Using Risk Stratification Based on a Multi-State Model of Genetic Variants (2015)
- Prostate
(A1 Refereed original research article in a scientific journal) - Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC (2015)
- British Journal of Cancer
(A1 Refereed original research article in a scientific journal)



